NHS. Cancer Survival in England, cancers diagnosed 2016 to 2020, followed up to 2021, https://digital.nhs.uk/data-and-information/publications/statistical/cancer-survival-in-england/cancers-diagnosed-2016-to-2020-followed-up-to-2021 Accessed 18th May, (2023).

Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.

Article  CAS  PubMed  Google Scholar 

Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163:386–402.e381.

Article  PubMed  Google Scholar 

Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O’Kane GM, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020;52:231–40.

Article  CAS  PubMed  Google Scholar 

Xu Z, Hu K, Bailey P, Springfeld C, Roth S, Kurilov R, et al. Clinical impact of molecular subtyping of pancreatic cancer. Front Cell Dev Biol. 2021;9:743908.

Article  Google Scholar 

O’Kane GM, Lowery MA. Moving the needle on precision medicine in pancreatic cancer. J Clin Oncol. 2022;40:2693–705.

Article  PubMed  Google Scholar 

Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Oncol. 2020;38:6002.

Article  Google Scholar 

Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30:558–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250–68.

Article  CAS  PubMed  Google Scholar 

Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1:EVIDoa2200043.

Article  PubMed  Google Scholar 

Mateo J, Bono JSD, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol. 2024;42:571–83.

Article  CAS  PubMed  Google Scholar 

Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2023;34:681–92.

Article  CAS  PubMed  Google Scholar 

DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim B-G, Oaknin A, et al. Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 Trial. J Clin Oncol. 2023;41:609–17.

Article  CAS  PubMed  Google Scholar 

Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:710–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.

Article  CAS  PubMed  Google Scholar 

Labori KJ, Bratlie SO, Andersson B, Angelsen J-H, Biörserud C, Björnsson B, et al. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2024;9:205–17.

Article  CAS  PubMed  Google Scholar 

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reiss KA, Mick R, O’Hara MH, Teitelbaum U, Karasic TB, Schneider C, et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39:2497–505.

Article  CAS  PubMed  Google Scholar 

Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394–405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown TJ, Yablonovitch A, Till JE, Yen J, Kiedrowski LA, Hood R, et al. The clinical implications of reversions in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2, or PALB2 after progression on rucaparib. Clin Cancer Res. 2023;29:5207–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hills SA, Diffley JF. DNA replication and oncogene-induced replicative stress. Curr Biol. 2014;24:R435–444.

Article  CAS  PubMed  Google Scholar 

Macheret M, Halazonetis TD. DNA replication stress as a hallmark of cancer. Annu Rev Pathol. 2015;10:425–48.

Article  CAS  PubMed  Google Scholar 

da Costa A, Chowdhury D, Shapiro GI, D’Andrea AD, Konstantinopoulos PA. Targeting replication stress in cancer therapy. Nat Rev Drug Discov. 2023;22:38–58.

Article  PubMed  Google Scholar 

Ngoi NYL, Pham MM, Tan DSP, Yap TA. Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends Cancer. 2021;7:930–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dreyer SB, Upstill-Goddard R, Paulus-Hock V, Paris C, Lampraki EM, Dray E, et al. Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology. 2021;160:362–377.e313.

Article  CAS  PubMed  Google Scholar 

Barnieh FM, Loadman PM, Falconer RA. Progress towards a clinically-successful ATR inhibitor for cancer therapy. Curr Res Pharm Drug Discov. 2021;2:100017.

Article  Google Scholar 

Yap TA, Fontana E, Lee EK, Spigel DR, Højgaard M, Lheureux S, et al. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023;29:1400–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 2017;31:318–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dillon MT, Guevara J, Mohammed K, Patin EC, Smith SA, Dean E et al. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J Clin Invest 2024;134:e175369.

Rückert F, Aust D, Böhme I, Werner K, Brandt A, Diamandis EP, et al. Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. J Surg Res. 2012;172:29–39.

Article  PubMed  Google Scholar 

Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pal K, Pletnev AA, Dutta SK, Wang E, Zhao R, Baral A, et al. Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth. Mol Cancer Ther. 2014;13:2264–75.

Article